VistaGen Therapeutics(US:VTGN) TMX Newsfile·2026-02-17 23:14Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc. due to allegations of misleading statements regarding the company's clinical trial results, which led to significant financial losses for investors [2][4]. Group 1: Legal Investigation - Faruqi & Faruqi is encouraging investors who purchased Vistagen securities between April 1, 2024, and December 16, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Vistagen, with a deadline of March 16, 2026, for investors to seek the role of lead plaintiff [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against Vistagen - The complaint alleges that Vistagen and its executives violated federal securities laws by making false and misleading statements about the likelihood of success for the fasedienol drug based on previous clinical trial results [4]. - The announcement on December 17, 2025, revealed that the PALISADE-3 study did not meet its primary efficacy endpoint, causing Vistagen's stock price to plummet over 81% to $0.88 per share [5].